Nordberg A, Wahlström G
Department of Pharmacology, Uppsala University, Sweden.
J Neural Transm Gen Sect. 1992;88(3):199-221. doi: 10.1007/BF01244733.
The aim of this review is to summarize the effects of acute and chronic treatment with barbiturates, ethanol and benzodiazepines on cholinergic mechanisms in the brains of experimental animals. A single dose of each of these substances reduces the turnover of ACh in the brain. Long-term treatment has the opposite effect; complicated interactions including decreased content of ACh are induced. Barbiturates have been shown to bind stereospecifically to muscarinic and nicotinic receptors in the brain, but this has not been observed for ethanol or the benzodiazepines. The effects on the cholinergic system are affected by the length of treatment and choice of treatment regimen. No effect on cholinergic parameters, such as muscarinic receptors, in the brain is observed on withdrawal of ethanol or barbiturate treatment when the animals are still tolerant towards the substances. The increase in the number of muscarinic receptors observed in several brain regions on withdrawal is seen as a sign of cholinergic supersensitivity. The number of receptors returns to normal when abstinence convulsions have occurred. The assumption of a cholinergic influence is supported by the finding that atropine, given as a single dose on the day of withdrawal of barbital, can prevent the muscarinic receptor changes. Furthermore, long-term barbital or ethanol treatment can induce permanent persistent changes in the cholinergic system in the brain. Cognitive defects and a significant permanent reduction in the content of ACh can be measured in rats which have had long-term barbital treatment. Similarly, a reduced number of muscarinic receptors has been measured in different brain regions of chronic alcoholics. Accumulating data support the role of the cholinergic system in expressing symptoms of physical dependence on barbiturates, ethanol and benzodiazepines as well as in the permanent long-term effects observed after end of treatment.
本综述的目的是总结巴比妥类药物、乙醇和苯二氮䓬类药物的急性和慢性治疗对实验动物大脑胆碱能机制的影响。这些物质中的每一种单次给药都会降低大脑中乙酰胆碱(ACh)的周转率。长期治疗则产生相反的效果;会引发包括ACh含量降低在内的复杂相互作用。已证明巴比妥类药物可立体特异性地与大脑中的毒蕈碱型和烟碱型受体结合,但乙醇或苯二氮䓬类药物未观察到这种情况。对胆碱能系统的影响受治疗时长和治疗方案选择的影响。当动物对乙醇或巴比妥类药物仍有耐受性时,停止这些药物治疗后,大脑中的胆碱能参数(如毒蕈碱型受体)未观察到影响。戒断时在几个脑区观察到的毒蕈碱型受体数量增加被视为胆碱能超敏反应的迹象。当发生戒断惊厥时,受体数量恢复正常。在巴比妥撤药当天单次给予阿托品可预防毒蕈碱型受体变化这一发现支持了胆碱能影响的假设。此外,长期给予巴比妥或乙醇治疗可导致大脑胆碱能系统发生永久性持续变化。长期接受巴比妥治疗的大鼠可检测到认知缺陷以及ACh含量显著永久性降低。同样,在慢性酒精中毒者的不同脑区也检测到毒蕈碱型受体数量减少。越来越多的数据支持胆碱能系统在表达对巴比妥类药物、乙醇和苯二氮䓬类药物身体依赖症状以及治疗结束后观察到的永久性长期影响中所起的作用。